Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of the Transdermal Compress device in participants with Transfemoral Amputations.


Clinical Trial Description

This study is a prospective, multicenter, single-arm, open-label study in skeletally mature participants with transfemoral limb loss (unilateral or bilateral), without bone or vascular disease who have or are anticipated to have rehabilitation problems with or cannot use a conventional socket prosthesis. Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participant progression including clinical assessments and prosthetic use will follow the study rehabilitation protocol. Events of special interest include superficial and deep infections at the implant site, failures, and secondary surgical interventions; participants will be followed for all soft tissue interface issues. Participants will be assessed for effectiveness and safety endpoints at baseline and at Months 6, 12, 18, and 24 and annually through 5 years post-implantation. Adverse events and adverse device effects will be collected and reported starting at the time of surgical implantation. Study participants will also be included in the Osseointegration Quality Registry in parallel to this study to allow for long-term follow-up post-study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06134167
Study type Interventional
Source Balmoral Medical company
Contact Kristen Gault
Phone (508) 351-8632
Email kristen.gault@avaniaclinical.com
Status Recruiting
Phase Phase 3
Start date June 2024
Completion date June 2031

See also
  Status Clinical Trial Phase
Completed NCT04067843 - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study N/A
Completed NCT04618276 - Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-II) N/A
Recruiting NCT05676801 - Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III) Early Phase 1